Fangusaro J, Jones DT, Packer RJ, et al. Pediatric low-grade glioma: State-of-the-art and ongoing challenges. Neuro-oncol. 2024;26(1):25–37.

Article  PubMed  Google Scholar 

Jones DTW, Kieran MW, Bouffet E, et al. Pediatric low-grade gliomas: next biologically driven steps. Neuro Oncol. 2018;20(2):160–73.

Article  CAS  PubMed  Google Scholar 

Packer RJ, Pfister S, Bouffet E, et al. Pediatric low-grade gliomas: implications of the biologic era. Neuro Oncol. 2017;19(6):750–61.

CAS  PubMed  Google Scholar 

Lindsay HB, Mohila CA, Chintagumpala M. MAPK pathway-targeted therapies for pediatric low grade gliomas. Pediatr Hematol Oncol J. 2023;8(2):97–101.

Article  Google Scholar 

Manoharan N, Liu KX, Mueller S, et al. Pediatric low-grade glioma: targeted therapeutics and clinical trials in the molecular era. Neoplasia. 2023;36: 100857.

Article  CAS  PubMed  Google Scholar 

Ryall S, Zapotocky M, Fukuoka K, et al. Integrated molecular and clinical analysis of 1,000 pediatric low-grade gliomas. Cancer Cell. 2020;37(4):569-83 e5.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Johnson A, Severson E, Gay L, et al. Comprehensive genomic profiling of 282 pediatric low- and high-grade gliomas reveals genomic drivers, tumor mutational burden, and hypermutation signatures. Oncologist. 2017;22(12):1478–90.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Davies H, Bignell GR, Cox C, et al. Mutations of the BRAF gene in human cancer. Nature. 2002;417(6892):949–54.

Article  CAS  PubMed  Google Scholar 

Yaeger R, Corcoran RB. Targeting alterations in the RAF-MEK pathway. Cancer Discov. 2019;9(3):329–41.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Sun Y, Alberta JA, Pilarz C, et al. A brain-penetrant RAF dimer antagonist for the noncanonical BRAF oncoprotein of pediatric low-grade astrocytomas. Neuro Oncol. 2017;19(6):774–85.

CAS  PubMed  PubMed Central  Google Scholar 

US Food & Drug Administration. FDA grants accelerated approval to tovorafenib for patients with relapsed or refractory BRAF-altered pediatric low-grade glioma [media release]. 23 Apr 2024. https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-tovorafenib-patients-relapsed-or-refractory-braf-altered-pediatric.

Day One Biopharmaceuticals I. OJEMDA (tovorafenib): US prescribing information. 2024. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/218033s000lbl.pdf. https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=218033. Accessed 9 May 2024.

Sunesis Pharmaceuticals I, Biogen I. Biogen Idec and Sunesis form collaboration to discover and develop multiple small molecule oncology products [media release]. 7 Sep 2004. http://www.sunesis.com.

Sunesis Pharmaceuticals I. Annual report. 2018. https://www.annualreports.com/HostedData/AnnualReportArchive/s/NASDAQ_SNSS_2018.pdf. Accessed 13 May 2024.

Sunesis Pharmaceuticals. Sunesis Pharmaceuticals reports fourth quarter and full-year 2019 financial results and recent highlights [media release]. 10 Mar 2020. https://markets.businessinsider.com/news/stocks/sunesis-pharmaceuticals-reports-fourth-quarter-and-full-year-2019-financial-results-and-recent-highlights-1028982778.

DOT Therapeutics-1. Asset transfer and license agreement. 2019. https://www.sec.gov/Archives/edgar/data/1845337/000119312521150017/d155073dex105.htm. Accessed 28 May 2024.

Day One Biopharmaceuticals. Day One Biopharmaceuticals shares plans to rapidly develop new cancer treatments for people of all ages and announces $60M Series A funding and lead clinical-stage program acquired through Takeda [media release]. 21 May 2020. https://ir.dayonebio.com/news-releases/news-release-details/day-one-biopharmaceuticals-shares-plans-rapidly-develop-new.

Day One Biopharmaceuticals. Day One announces cooperative research and development agreement with National Cancer Institute to expand development of tovorafenib (DAY101) [media release]. 17 Oct 2022. https://ir.dayonebio.com/news-releases/news-release-details/day-one-announces-cooperative-research-and-development-agreement.

Foundation Medicine. Foundation Medicine and Day One Biopharmaceuticals announce global collaboration to advance pediatric cancer care [media release]. 21 Sep 2022. https://www.foundationmedicine.com/press-releases/foundation-medicine-and-day-one-biopharmaceuticals-announce-global-collaboration-to-advance-pediatric-cancer-care#.

Rastogi S, Perino S, Lal-Nag M, et al. Preclinical activity of the type II RAF inhibitor tovorafenib in tumor models harboring either a BRAF fusion or a NF1-LOF mutation [abstract no. 1972]. Cancer Res. 2024;84(6 Suppl):1972.

Article  Google Scholar 

Kilburn LB, Khuong-Quang DA, Hansford JR, et al. The type II RAF inhibitor tovorafenib in relapsed/refractory pediatric low-grade glioma: the phase 2 FIREFLY-1 trial. Nat Med. 2024;30(1):207–17.

Article  CAS  PubMed  Google Scholar 

Kilburn L, Khuong-Quang D-A, Nysom K, et al. Clinical activity of pan-RAF inhibitor tovorafenib in the registrational pediatric low-grade glioma arm of the phase 2 FIREFLY-1 (PNOC026) study [abstract no. 10004 plus oral presentation]. J Clin Oncol. 2023;41(16 Suppl):10004.

Article  Google Scholar 

Nysom K, Kilburn L, Leary S, et al. Clinical activity and safety of the RAF inhibitor tovorafenib in patients with optic pathway gliomas in the registrational pediatric low-grade glioma arm of the phase 2 FIREFLY-1 (PNOC026) study [abstract no. CTNI-24 and oral presentation]. Neuro-oncol. 2023;25(Suppl 5):v79.

Article  Google Scholar 

Wright K, Zimmerman M, Fine E, et al. Type II BRAF Inhibitor TAK-580 shows promise for upcoming clinal trial as evidenced by single patient IND study [abstract no. LGG-26]. Neuro-oncol. 2018;20(suppl_2):i110.

Article  PubMed Central  Google Scholar 

Wright K, Krzykwa E, Greenspan L, et al. Phase I study of DAY101 (TAK580) in children and young adults with radiographically recurrent or progressive low-grade glioma (LGG) [abstract no EPCT-01]. Neuro-oncol. 2020;22(Suppl 3):iii304.

Article  PubMed Central  Google Scholar 

Krzykwa E, Korn RL, Blackman SC, et al. Initial radiographic assessment of DWI and ADC values in children and young adults treated with DAY101 (TAK-580) for recurrent low-grade gliomas (LGG) harboring MAPK alterations [abstract no IMG-05]. Neuro-oncol. 2020;22(Suppl 3):355–6.

Article  Google Scholar 

Wright K, Kline C, Abdelbaki M, et al. PNOC014: Phase Ib study results of DAY101(tovorafenib) for children with low-grade gliomas (LGGS) and other RAS/RAF/MEK/ERK pathway-activated tumors [abstract no. CTNI-53 ]. Neuro-oncol. 2022;24(Suppl 7):vii84.

Article  Google Scholar 

Lee J, Ammakkanavar N, Saini A, et al. Clinical activity of the type II pan-RAF inhibitor tovorafenib in BRAF-fusion melanoma [abstract no. 174 plus poster]. In: 19th European Association of Dermato-Oncology (EADO) Congress. 2023.

Day One Biopharmaceuticals I. Day One reports third quarter 2023 financial results and corporate progress [media release]. 6 Nov 2023. https://ir.dayonebio.com/news-releases/news-release-details/day-one-reports-third-quarter-2023-financial-results-and#:~:text.

Rasco DW, Medina T, Corrie P, et al. Phase 1 study of the pan-RAF inhibitor tovorafenib in patients with advanced solid tumors followed by dose expansion in patients with metastatic melanoma. Cancer Chemother Pharmacol. 2023;92(1):15–28.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Offer K, McGuire MT, Song K, et al. Activity of Type II RAF inhibitor tovorafenib in a pediatric patient with a recurrent spindle cell sarcoma harboring a novel SNX8-BRAF gene fusion. JCO Precis Oncol. 2023;7(e2300065):1–5.

Google Scholar 

van Eijkelenburg NKA, van der Lugt J, Costa DD, et al. Preliminary clinical activity of the type II RAF inhibitor tovorafenib in RAF fusion-driven recurrent/progressive sarcomas. In: CTOS Annual Meeting. 2023.

van Tilburg CM, Kilburn LB, Perreault S, et al. LOGGIC/FIREFLY-2: a phase 3, randomized trial of tovorafenib vs. chemotherapy in pediatric and young adult patients with newly diagnosed low-grade glioma harboring an activating RAF alteration. BMC Cancer. 2024;24(1):147.

Article  PubMed  PubMed Central  Google Scholar